TY - JOUR
T1 - Therapierelevante unterschiede bei betablockern und ACE-hemmern: Innovation oder plagiat?
AU - Dominiak, P.
AU - Dendorfer, A.
AU - Raasch, W.
PY - 2002/1/17
Y1 - 2002/1/17
N2 - As exemplified by the two classes of substance beta blockers and ACE inhibitors, the question is considered as to when new developments within a drug family can be termed innovations and when they must be seen purely as plagiarisms ("me-too" preparations). It is noted that in principle no innovations are to be expected from generics, since these substances are are not the subject of specific research. Although large-scale clinical studies in recent years have identified a new indication - cardiac insufficiency - for the beta blockers metoprolol, bisoprolol and carvedilol, this must not be considered an innovation in the sense of a new development. The translatability of the study results to uninvestigated substances is uncertain. In contrast to the beta blockers, the indications for the ACE inhibitors have long been known, but again, the new generic preparations that have come onto the market are not innovations.
AB - As exemplified by the two classes of substance beta blockers and ACE inhibitors, the question is considered as to when new developments within a drug family can be termed innovations and when they must be seen purely as plagiarisms ("me-too" preparations). It is noted that in principle no innovations are to be expected from generics, since these substances are are not the subject of specific research. Although large-scale clinical studies in recent years have identified a new indication - cardiac insufficiency - for the beta blockers metoprolol, bisoprolol and carvedilol, this must not be considered an innovation in the sense of a new development. The translatability of the study results to uninvestigated substances is uncertain. In contrast to the beta blockers, the indications for the ACE inhibitors have long been known, but again, the new generic preparations that have come onto the market are not innovations.
UR - https://www.scopus.com/pages/publications/0037122672
M3 - Kurzer Abriss
C2 - 11847884
AN - SCOPUS:0037122672
SN - 1438-3276
VL - 144
SP - 50
EP - 54
JO - MMW-Fortschritte der Medizin
JF - MMW-Fortschritte der Medizin
IS - 1-2
ER -
SDG 3 Good Health and Well-being